Reach Us +44-7426-607635
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Cladribine in the Treatment of Langerhans Cell Histiocytosis: A Summary of the Literature

Langerhans cell Histiocytosis (LCH) is a rare disease for which treatment with 2- chlorodeoxyadenosine (cladribine) has changed disease outcome. Cladribine has meanwhile been administered over two decades and is available for intravenous and subcutaneous administration. Cladribine has been administered in treatment of therapy naïve, relapsed and refractory LCH and induces high response rates, regardless of prior treatment. Literature describing the use of cladribine either alone or in combination with cytarabine is summarized herein.


Marlies E.H.M. van Hoef

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
Flyer image

Abstracted/Indexed in

  • Index Copernicus
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • Publons
  • Secret Search Engine Labs